Five Radiation Treatments Match 26 for Localized Prostate Cancer, Miami HEAT Trial Finds
Summary
- A phase 3 trial shows five radiotherapy sessions work as well as 26 for controlling prostate cancer.
- The shorter treatment may reduce side effects and improve patient experience through fewer visits.
- Findings suggest radiotherapy can be delivered more efficiently without compromising outcomes.
Cancer radiotherapy often unfolds like a slow, steady glow, dispersed over weeks, each session adding another layer of carefully measured energy. But what if radiation treatment could be delivered in more concentrated bursts over a shorter period of time without losing its impact?
That is the question at the heart of the Miami HEAT trial, whose interim results were presented May 18, 2026, at the European Society for Radiotherapy and Oncology Congress (ESTRO) in Stockholm, Sweden. The international, phase 3 study developed at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, explores whether the structure of radiotherapy can be reshaped for men with localized prostate cancer.
Matthew Abramowitz, M.D., researcher at Sylvester, associate professor of radiation oncology at the Miller School and principal investigator of the HEAT trial, presented the trial’s primary outcomes. The study compares two approaches to hypofractionated radiotherapy,ne extended over 26 treatments and the other delivered in just five.
At first glance, the difference is stark. One approach stretches across weeks. The other is completed in a handful of sessions.
“The core question,” Dr. Abramowitz said, “is whether we can concentrate treatment in a way that preserves effectiveness while reducing the burden on patients.”
Concentrating the Dose
Radiation oncology has long balanced precision with caution. Delivering too much, too quickly risks damaging healthy tissue. Spreading treatment out allows the body time to recover between sessions. Advances in imaging, planning and delivery are beginning to shift that balance.
The Miami HEAT trial builds on those advancements. Its interim findings show that five-fraction accelerated hypofractionated radiotherapy achieves non-inferior prostate cancer control compared to the traditional 26-fraction regimen. In other words, the five-treatment approach performs just as well in preventing biochemical failure, a key indicator of cancer recurrence.
For appropriately selected patients with low- to intermediate-risk disease, that difference could reshape the treatment experience.
“We’re seeing that modern techniques allow us to deliver treatment with remarkable precision,” said Allan Pollack, M.D., Ph.D., Sylvester researcher, co-PI of the study and professor of radiation oncology at the Miller School. “Which opens the door to rethinking how best to treat prostate cancer since, radiobiologically, prostate cancer is more responsive when the doses per treatment are higher each day, as compared to the nearby normal tissues.”
Seeing Beyond the Clinical Data
But tumor control is only part of the story.
Dr. Abramowitz presented clinician-reported outcomes, including measures of toxicity, while David Lee, M.D., chief resident in radiation oncology, shared patient-reported outcomes. These measures use standardized surveys to capture symptoms, function and overall quality of life, offering insight into the patient experience.
Together, these data points show not just whether treatment works but how it is lived.
The results suggest that the accelerated approach may also soften some of the immediate impact of treatment. Patients receiving the five-fraction regimen experienced improved acute gastrointestinal toxicity. Late toxicity outcomes were comparable between the two groups.
In practical terms, the shorter course seems to deliver comparable outcomes without intensifying long-term side effects and may reduce near-term discomfort.
“Patients measure treatment in very real terms,” Dr. Abramowitz said. “It’s about how they feel day to day, not just what the numbers show. That perspective is central to how we evaluate success.”
A Global Effort in Focus
The Miami HEAT trial reflects a collaboration that spans continents. Investigators from the University of Turin in Italy and the Northern Sydney Cancer Centre in Australia joined Sylvester researchers in bringing the study to life.
The importance of the trial was underscored by its reception at ESTRO 2026. The study’s abstract was recognized as a top abstract, placing it in the top 5 percent of submissions at what was described as the most competitive congress in the organization’s history.
“The recognition highlights both the quality of the research and the relevance of its findings,” said Dr. Pollack. “As prostate cancer remains one of the most common cancers in men, even incremental improvements in treatment delivery can have far-reaching impact.”
For clinicians, the preliminary data support accelerated hypofractionation as a well-tolerated standard-of-care option for appropriately selected patients. For patients, the findings suggest something equally important: the possibility of less time in treatment without sacrificing outcomes.
“The Miami HEAT trial ultimately reframes how treatment intensity is understood,” Dr. Abramowitz said. “Rather than asking how long therapy should stretch, it asks how most efficiently and effectively it can be delivered. What once required weeks may, for some patients, be achieved in days.”
More from the Miller School of Medicine
Researchers at Sylvester map how IDH-mutant gliomas evolve after treatment, revealing why tumors recur and pointing to precision cancer care.
As she graduates from the Miller School of Medicine, Kaylie Cullison, M.D./Ph.D, applies imaging science to personalize brain cancer care.
Sylvester physicians use adaptive radiation therapy and daily imaging to adjust cancer treatment in real time.
Sylvester Comprehensive Cancer Center scientists used nanoparticles to target pancreatic tumors and destroy cancer cells.
Tags: cancer research, Dr. Matt Abramowitz, Newsroom, prostate cancer, Radiation oncology, Sylvester Comprehensive Cancer Center